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Abstract
Background: Behavioral interventions that promote adherence to antiretroviral medications may decrease HIV treatment
failure. Antiretroviral treatment programs in sub-Saharan Africa confront increasing financial constraints to provide
comprehensive HIV care, which include adherence interventions. This study compared the impact of counseling and use of
an alarm device on adherence and biological outcomes in a resource-limited setting.
Methods and Findings: A randomized controlled, factorial designed trial was conducted in Nairobi, Kenya. Antiretroviral-
naı ¨ve individuals initiating free highly active antiretroviral therapy (HAART) in the form of fixed-dose combination pills (d4T,
3TC, and nevirapine) were randomized to one of four arms: counseling (three counseling sessions around HAART initiation),
alarm (pocket electronic pill reminder carried for 6 months), counseling plus alarm, and neither counseling nor alarm.
Participants were followed for 18 months after HAART initiation. Primary study endpoints included plasma HIV-1 RNA and
CD4 count every 6 months, mortality, and adherence measured by monthly pill count. Between May 2006 and September
2008, 400 individuals were enrolled, 362 initiated HAART, and 310 completed follow-up. Participants who received
counseling were 29% less likely to have monthly adherence ,80% (hazard ratio [HR]=0.71; 95% confidence interval [CI]
0.49–1.01; p=0.055) and 59% less likely to experience viral failure (HIV-1 RNA $5,000 copies/ml) (HR 0.41; 95% CI 0.21–0.81;
p=0.01) compared to those who received no counseling. There was no significant impact of using an alarm on poor
adherence (HR 0.93; 95% CI 0.65–1.32; p=0.7) or viral failure (HR 0.99; 95% CI 0.53–1.84; p=1.0) compared to those who did
not use an alarm. Neither counseling nor alarm was significantly associated with mortality or rate of immune reconstitution.
Conclusions: Intensive early adherence counseling at HAART initiation resulted in sustained, significant impact on
adherence and virologic treatment failure during 18-month follow-up, while use of an alarm device had no effect. As
antiretroviral treatment clinics expand to meet an increasing demand for HIV care in sub-Saharan Africa, adherence
counseling should be implemented to decrease the development of treatment failure and spread of resistant HIV.
Trial registration: ClinicalTrials gov NCT00273780
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The introduction of antiretroviral medications on a public
health scale to treat HIV-positive persons in sub-Saharan Africa
has been accompanied by concern that these actions will result in
widespread viral resistance because of poor adherence [1].
However, recent studies have shown that adherence is high in
African HIV treatment programs and often better than in Western
HIV clinics [2,3]. In a meta-analysis of 27 cohorts from 12 African
countries, adequate adherence was noted in 77% of participants
compared to only 55% among 31 North America cohorts [4].
Among individuals with imperfect adherence, the choice of
antiretroviral regimens may impact the development of antiretro-
viral resistance. In resource-limited settings, most antiretroviral
regimens contain non-nucleoside reverse transcriptase inhibitors
(NNRTI) [5–7]. NNRTI drugs such as nevirapine or efavirenz
have a long half-life in vivo; the concentrations of nevirapine in
plasma may remain for weeks after single-dose administration [8].
Thus, antiretroviral resistance may not occur in patients on
NNRTI regimens until their adherence drops to intermediate
levels below 80% [9]. This adherence differs significantly from the
more stringent adherence requirements ($95%) of regimens based
on unboosted protease inhibitors (PI) [10–13], and may allow
more lapses to occur in resource-limited settings where NNRTI-
based regimens are widely used.
Given these findings, antiretroviral treatment programs in sub-
Saharan Africa may be spending valuable resources promoting
adherence [14,15]. Targeted adherence interventions require
trained staff, space to accommodate confidentiality, and time on
the part of the patient and counselor. In a rapidly growing, large-
scale treatment program, these efforts could be a costly, rate-
limiting step in the enrollment of newly diagnosed HIV-positive
patients requiring care [16,17]. Although many antiretroviral
treatment programs in this setting include adherence interventions
with medications [18–20], there is limited quality evidence that
any of these methods improve long-term adherence to highly
active antiretroviral therapy (HAART) [21–24]. This information
is essential as HIV clinics in sub-Saharan Africa are forced to
deliver antiretroviral treatment with increasingly limited funding
[25–27].
Inexpensive adherence interventions need to be identified that
are proven to be effective in resource-limited settings. Counseling
is widely implemented in HIV treatment programs in Africa, but
delivery of this intervention is not uniform and its impact on
improving adherence is unclear. There is some evidence that early
intensive counseling around the time of HAART initiation may be
beneficial [28]. In addition, it has been suggested that alarm
devices, which are relatively inexpensive and easy to distribute,
may improve pill adherence in Kenya [29]. In order to con-
currently evaluate the value of these distinct adherence interven-
tions in a resource-limited setting, we conducted a factorial
randomized trial in Nairobi, Kenya and compared impact of
adherence counseling and the use of an alarm device on adherence
and biological outcomes.
Methods
Setting and Recruitment
The trial was conducted between May 2006 and September
2008 at the Coptic Hope Center for Infectious Diseases in Nairobi,
Kenya (Texts S1 and S2). The Hope Center is an HIV treatment
clinic established in 2004 by the University of Washington and the
Coptic Orthodox Mission. Supported by the President’s Emer-
gency Plan for AIDS Relief (PEPFAR), the Hope Center provides
free HIV care and antiretroviral treatment. Clinic procedures have
been described elsewhere [30]. As per Kenyan national guidelines,
newly diagnosed clients are initiated on free NNRTI-based
HAART if they have: a CD4 count ,250 cells/mm
3, World
Health Organization (WHO) clinical stage IV disease, or a CD4
count ,350 cells/mm
3 with WHO clinical stage III disease [31].
Individuals were eligible to enroll in the study if they were $18 y
of age, antiretroviral naı ¨ve, agreed to home visits, and planned to
live in Kenya for at least 2 y.
Design
The study evaluated two interventions based on models of
cognitive and behavioral theory to promote adherence to
antiretroviral medications: intensive adherence counseling and
use of a pocket alarm device [32,33]. In a 262 factorial design,
participants were randomized in a 1:1:1:1 ratio to one of four arms
prior to initiating HAART: (1) adherence counseling alone; (2)
alarm device alone; (3) both adherence counseling and alarm
device together; and (4) a control group that received neither
adherence counseling nor alarm device. Randomization was
performed at enrollment by the study nurse who opened a sealed
envelope containing a computer-generated block randomization
code that was developed by the study biostatistician. Study
investigators and participants were not blinded to the interven-
tions. The prespecified primary endpoints for this study were
adherence as measured by monthly manual pill counts, plasma
HIV-1 RNA, and CD4 count.
Interventions
In the adherence counseling intervention, trained counselors
administered two counseling sessions to participants prior to
HAART initiation and a third session one month after HAART
initiation (Text S1). Counseling sessions around HAART initiation
were based on a model of successful antiretroviral adherence
promotion at a large University of Washington-affiliated HIV
treatment program in Seattle, Washington [28]. All counseling
sessions followed a written standardized protocol and lasted
between 30 and 45 min. In the first session, counselors explored
personal barriers to good adherence and taught participants about
the HIV, the virus that causes AIDS, antiretroviral medications,
and the risks of treatment failure due to poor adherence. The
second session occurred on a separate day and involved a review of
a participant’s understanding and readiness to begin antiretroviral
medications. The third session allowed the counselor to examine
practical and personal issues that the participant may have
encountered on HAART. The adherence counseling intervention
had been previously used and adapted at the same site in Kenya
for over 2 y and was delivered in English and Kiswahili.
Participants in the alarm device intervention received a small
pocket digital alarm, the ALRT PC200 (ALR Technologies Inc),
which the individual was to carry at all times for 6 mo duration.
The device was programmed by the study staff to beep and flash
twice a day at a time convenient to the participant when
medications were to be taken. The digital alarm could not be
reprogrammed or inactivated by the individual and was utilized
for 6 mo after HAART initiation before being disabled by study
staff.
Control
At HAART initiation, the study pharmacist explained the side
effects of medications and problems associated with poor
adherence in a 15-min session prior to dispensing drugs. All
participants, including those in the control arm, received this
Counseling and Alarm on Adherence: An RCT
PLoS Medicine | www.plosmedicine.org 2 March 2011 | Volume 8 | Issue 3 | e1000422educational message. Participants randomized to the control
group did not receive adherence counseling or an alarm device.
Follow-up
At enrollment, participants signed a written informed consent,
had blood drawn for HIV-1 RNA levels and CD4 count, and
shared information on sociodemographic characteristics, risk
behavior, and distance from clinic. After initiating HAART,
participants returned to the study clinic at monthly intervals with
their pill bottles to pick up antiretroviral medications. At each
monthly visit, the study pharmacist counted and recorded the
number of pills remaining in the bottle, the visit date, whether the
participant took his or her morning dose, and the number of pills
dispensed that day. Participants randomized to receive an alarm
device were asked if they had been using the device at each of
these monthly visits, and any defective, lost, or stolen devices were
replaced at this time. Blood was drawn for CD4 count and HIV-1
RNA at 6, 12, and 18 mo after HAART initiation. Participants
were followed for 18 mo on HAART before exiting the study.
HIV-1 RNA was measured using the Gen-Probe quantitative
HIV-1 viral load assay [34]. CD4 counts were determined using
flow cytometry (FACScan, Becton Dickinson).
Endpoints
Adherence was calculated at each pharmacy refill visit as the
percentage of dispensed doses that were taken since the previous
visit to the study pharmacy. Total time between the last date the
participant was in the pharmacy and the participant’s subsequent
pharmacy visit included any missed visits to the pharmacy or time
when the participant was not attending the clinic. This calculated
adherence was assumed to be constant and the same as daily
adherence throughout this time period. Continuous adherence
and time to monthly adherence ,80% and ,95% were calculated
[10–13]. Viral failure was defined as the first plasma HIV-1 RNA
level $5,000 copies/ml measured at least 4 mo after HAART
initiation [35]. Other study endpoints included mortality and
change in CD4 count.
Statistical Methods
All analyses were modified intent-to-treat in that only
individuals who initiated HAART, and therefore had pill count
data collected for adherence measurement, were included in the
analyses. Data from all participants were utilized in analyses until
time of exit either because of completion of the study, loss to
follow-up, or death. Because of the factorial design of the study,
models to evaluate the study interventions were developed by first
testing the statistical interaction between those who received
counseling and those who received alarm. In all models, the
interaction term had a p-value larger than 0.20 and therefore was
dropped from the model. Accordingly, following the factorial
design of the study, those who received counseling were compared
against those who received no counseling and those who received
an alarm device were compared against those who received no
alarm. Analyses of discrete time-to-viral-failure event models were
performed using SAS 9.2; all other analyses were performed using
StataSE v10 (StataCorp).
Univariate comparisons were done using the Mann Whitney U
test for continuous variables, and Chi square tests for binary
variables. Baseline characteristics were compared between inter-
ventions and if there were statistically significant differences (i.e.,
an imbalance in a variable at baseline), then these variables were
tested to see if they also related to the various outcomes of interest
(adherence, mortality, viral load, and CD4 count). If baseline
variables met both criteria (imbalanced at baseline and related to
outcome), then they were included in a multivariable model [36].
When comparing counseling versus no counseling, the only
variable that met both criteria was age in the analysis of CD4
count. When comparing alarm device versus no alarm device, the
only variables that met these criteria were ever having given or
received money/favors in exchange for sex in the adherence
analyses and baseline plasma viral load in the viral load and
mortality analyses.
Analyses of time to monthly adherence ,80% and ,95%, viral
failure, and death were performed using Cox proportional hazards
models. Kaplan-Meier methods were used to create time to event
graphs. Longitudinal analyses of adherence were performed using
generalized estimating equations (GEE) with an exchangeable
correlation matrix and robust variance estimate. Linear regression
was used to assess differences in change in CD4 count.
The sample size was calculated as follows. Given information
from previous studies [3,29,37], it was estimated that approxi-
mately 60% of participants would maintain adherence $95%
without intervention and that the interventions would help 82%–
94% of the participants maintain $95% adherence. Assuming a
two-sided test with a=0.05, 74 participants were needed in each
arm to have 80% power to detect a 22% difference (60% versus
82%). One hundred participants were randomized to each arm to
allow for loss to follow-up and mortality.
Ethical Review
The study protocol was reviewed and approved by the
institutional review boards at the University of Washington and
Kenyatta National Hospital (Nairobi, Kenya).
Results
Study Population
Enrollment of participants began on May 2006 and ended on
November 2006 during which time 1,096 patients were deemed
eligible to receive HAART at the Hope Center (Figure 1). Of these
patients, 457 were eligible to participate in the study and 400
accepted study enrollment. The 400 participants were randomized
to one of four study arms with each arm containing 100
participants. 639 patients were ineligible for the study because
they were HAART experienced (55%), lost to follow-up before
study recruitment (19%), under 18 y of age (14%), on antituber-
culosis medications (11%), unwilling to initiate HAART (1%), or
mentally impaired (,1%). Study follow-up was completed in
September 2008 as per the study protocol.
362 participants initiated HAART (a generic fixed-dose
combination pill containing d4T, 3TC, and nevirapine) and were
included in analyses of the study endpoints (Table 1). In this study
population, 66% were female, the median age was 36 y
(interquartile range [IQR] 31–42), the median monthly rent was
US$28 (IQR 11–56), the median distance from home to clinic was
10 kilometers (IQR 6–15), and 10% had ever given or received
money/favors in exchange for sex. Of the 362 HAART initiators:
347 (96%) visited the study pharmacy at least two times and
consequently could have adherence calculated; 359 (99%) had
plasma viral levels collected at enrollment; and 331 (91%) had at
least one follow-up CD4 count measurement. The mean
adherence for the 347 participants who had adherence calculated
was 92.5% (95% confidence interval (CI) 91.2–94.0) and the
median adherence was 97.3% (IQR 93.5–98.7); 314 participants
(90.5%) had overall adherence $80%; and 237 (68.3%) had
overall adherence $95%.
For all endpoint analyses, the interaction term between
counseling and alarm was tested and not statistically significant.
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counseling and counseling plus alarm arms) were compared to
those who received no counseling (participants from the alarm and
control arms) and those who received an alarm device (participants
from the alarm and counseling plus alarm arms) were compared to
those who received no alarm (participants from the counseling and
control arms).
Loss to Follow-up
At the end of study follow-up, there were 52 patients who were
lost to follow-up and 38 deaths (Figure 1). In a comparison of
baseline characteristics, such as age, gender, income, education,
distance, and sexual behavior, there were no significant differences
between those lost and those retained except the former were more
likely to have a higher rent (median US$, 46 versus 25; p=0.002)
and fewer people per household (3 versus 4; p=0.02). Prior to
HAART initiation, 29 (7%) participants were lost to follow-up and
nine (2%) died. Monthly rent was higher among those who did not
initiate HAART compared to those who did (median US$,4 2
versus 28; p=0.03).
Intervention Participation
200 participants were randomized to the adherence counseling
intervention and 164 (82%) received all three assigned counseling
sessions, 21 (10.5%) received two sessions, seven (3.5%) received
one session, and eight (4%) did not undergo any sessions. All of
those who did not receive all three counseling sessions died or were
lost to follow-up before completing the intervention.
200 participants were randomized to receive the alarm device
intervention and to use it for 6 mo after HAART initiation. 29
individuals died or were lost to follow-up before the pocket alarm
was used. Among those who used the external reminder, 150
(88%) reported using it for 5 to 6 mo after HAART initiation: 107
(63%) reported using the alarm at all monthly follow-up visits over
6 mo, 43 (25%) reported not using the device at one visit, 11 (6%)
at two visits, seven (4%) at three visits, and three (2%) at four visits.
Reasons for not using the pocket alarm included: the device not
working properly (72%), stolen (11%), lost (6%), no reason (6%),
forgot (2%), no need (2%), and unable (1%). There were no
reports of not using an alarm device because of stigma and all
participants requested to keep the inactivated alarm device for use
as a pocket watch after the 6-month intervention had ended.
There was no harm or unintended effect recorded for either
intervention.
Counseling
In longitudinal analysis, adherence during the first month after
initiating HAART was significantly higher among those who
received counseling (difference in intercepts, 3.58%; 95% CI
0.50%–6.66%; p=0.023) compared to those who did not receive
counseling, and this difference was constant over 18 mo follow-up
(difference in slopes, 0.13% per month; 95% CI 20.16% to
0.42%; p=0.4) (Figure 2A). Those participants receiving counsel-
ing were on the margin of significance for being 29% less likely to
experience monthly adherence ,80% over 18 mo follow-up
compared to those who received no counseling (hazard ratio [HR]
0.71; 95% CI 0.49–1.01; p=0.055) (Figure 3A; K-M log-rank
p=0.053). No significant differences were found in adherence
,95% between those who received counseling and those who did
not (HR 0.89; 95% CI 0.70–1.12; p=0.3).
Participants who received counseling were 59% less likely to
experience viral failure (HIV-1 RNA $5,000 copies/ml) than
those who did not receive counseling (HR 0.41; 95% CI 0.21–
0.81; p=0.01) (Figure 3B). Significant differences were also found
after setting viral failure at a lower threshold of HIV-1 RNA
$1,000 copies/ml (HR 0.45; 95% CI 0.24–0.82; p=0.01).
There was no significant difference in mortality between those
who received counseling and those who did not (HR 0.87; 95% CI
0.42–1.81; p=0.7) (Figure 3C). There was also no significant
difference in CD4 count increase at 18 mo follow-up between
Table 1. Baseline characteristics among 362 HAART initiators.
Characteristic Counseling (n=92) Alarm (n=91)
Counseling and
Alarm (n=83) Control (n=96)
Age, y 36 (31–44) 36 (32–41) 38 (32–44) 35 (30–40)
n (%) female 54 (59) 62 (68) 55 (66) 68 (71)
Education, y 12 (8–14) 12 (8–14) 11 (8–13) 12 (8–13)
n (%) unemployed 31 (34) 27 (30) 22 (27) 40 (42)
n (%) married or attached 43 (47) 50 (55) 42 (51) 51 (53)
Monthly rent, US$ 28 (13–56) 25 (11–70) 23 (10–56) 28 (11–56)
n (%) flush toilet 47 (51) 41 (45) 35 (42) 39 (41)
Individuals living in household 4 (3–5) 3 (2–5) 4 (2–5) 4 (3–5)
n (%) cost of travel to clinic $US$.70* 59 (64) 49 (54) 62 (75) 52 (54)
Distance from home to clinic, kilometer** 11 (7–15) 9 (5–15) 11 (8–16) 10 (6–13)
Age at first sex, y 18 (16–20) 18 (16–20) 18 (16–20) 18 (16–20)
Lifetime sexual partners 4 (2–8) 4 (2–5) 4 (3–8) 4 (2–6)
n (%) ever exchanged money or favors for sex 12 (13) 5 (6) 7 (8) 13 (14)
Plasma HIV-1 viral load, copies/ml 627,200 (202,300–1,349,200) 402,050 (161,200–782,600) 441,600 (95,100–1,047,200) 473,200 (234,700–1,264,650)
CD4 count, cells/ml 113 (63–171) 115 (46–190) 131 (70–190) 114 (67–173)
Data are median (range), unless otherwise indicated.
*p=0.01
**p=0.05
doi:10.1371/journal.pmed.1000422.t001
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CD4 cells/ml increase, 202 versus 225; p=0.7), and this lack of
significant difference remained in multivariable modeling control-
ling for age at baseline (unpublished data).
Alarm Device
There was no significant difference in any of the study endpoints
between those who received alarm device and those who did not
(Figure 3). In longitudinal analysis, adherence during the first
month after initiating HAART did not differ between those who
received an alarm device and those who did not (difference in
intercepts, 0.77%; 95% CI 22.36% to 3.89%; p=0.6), and this
lack of difference continued over 18 mo follow-up (difference in
slopes,20.15% per month; 95% CI 20.45% to 0.15%; p=0.3)
(Figure 2B). Those who received an alarm device were no less
likely to experience monthly adherence ,80% over 18 mo follow-
up compared to those who received no alarm device (HR 0.93;
95% CI 0.65–1.32; p=0.7), even after adjusting for baseline
differences of ever having given or received money/favors in
exchange for sex (adjusted hazard ratio [aHR] 0.95; 95% CI 0.66–
1.35; p=0.8]. In addition, there was no significant difference in
time to viral failure $5,000 copies/ml (HR 0.99; 95% CI 0.53–
1.84; p=1.0), death (HR 0.76; 95% CI 0.36–1.60; p=0.5),
immunological recovery (median CD4 count cells/ml increase,
197 versus 227; p=0.2), and adherence ,95% (HR 0.97; 95% CI
0.77–1.22; p=0.8) between those who received an alarm device
and those who did not. These results remained unchanged in
multivariable analyses and at a viral failure threshold of HIV-1
RNA $1,000 copies/ml (unpublished data).
Discussion
In this randomized controlled trial comparing counseling and
the use of an alarm device to improve adherence to antiretroviral
medications in Kenya, participants receiving intensive early
adherence counseling were 59% (HR 0.41; 95% CI 0.21–0.81;
p=0.01) less likely to experience viral failure, demonstrating the
powerful impact of this behavioral intervention on biological
outcomes. Although poor adherence has been associated with
plasma HIV-1 viral rebound and development of viral resistance
[38,39], few trials have demonstrated an association between an
intervention designed to improve adherence and virologic impact
[37,40–42]. This study found a significant association between
having received adherence counseling and antiretroviral treatment
failure as defined by the WHO [35].
Those receiving adherence counseling in this study were 29%
(HR 0.71; 95% CI 0.49–1.01; p=0.055) less likely to experience
poor adherence compared to those who received no counseling.
The positive effects of counseling on adherence in this study were
found immediately after HAART initiation and were sustained
over 18 mo. Trained counselors provided not only didactic
information but discussed barriers to good adherence and
developed a relationship with participants through one-on-one
interviews conducted over 2 mo. Motivating individuals to change
their behavior through counseling appears to give individuals tools
they need to improve their adherence [43]. Dedicating time
towards effective communication regarding adherence may
strengthen a provider-patient relationship that, in turn, promotes
adherence through trust [44]. These findings support the
implementation of adherence counseling among HIV clinics in
sub-Saharan Africa and suggest that forms of relationship-
strengthening adherence interventions should be continued, even
in the setting of increasing resource constraints.
An intervention that reduces viral failure by more than half
represents significant cost savings both from the deferred purchase
of more expensive second-line antiretroviral medications and the
potential expense of treating opportunistic reinfections. Compared
to the costs of treatment failure, employing counselors in this
setting is relatively inexpensive. Using tents where necessary to
preserve confidentiality and having one counselor interact with
groups of patients in the first session further decreases costs. Thus,
upfront investment in adherence counseling could save programs
from future financial losses due to treatment failure that, without
counseling, could double. Our study also demonstrates that the
best method of ‘‘treatment preparedness’’ as recommended by the
WHO [35], is not simply educating patients about antiretroviral
drugs, side effects, and adherence, as was given to all participants
in this study. Instead, two interactive, anticipatory sessions of
counseling prior to HAART and a session 1 mo after HAART
initiation may better prepare a patient in a resource-limited setting
to adhere to a lifetime of antiretroviral drugs.
In contrast to counseling, our study did not find any beneficial
effect of using an external alarm device on adherence or viral
failure. This result concurs with recent studies and reviews that
find limited impact or insufficient evidence to demonstrate the
effectiveness of using an external reminder alone [40,45,46].
Although the pocket alarms were widely accepted and used by
Figure 2. Lowess curves of percent adherence over time in
months since HAART initiation by intervention. Thick lines
indicate average percent adherence. Thin lines indicate 95% CIs. Solid
lines indicate intervention. Dashed lines indicate no intervention. (A)
Counseling versus no counseling. (B) Alarm versus no alarm.
doi:10.1371/journal.pmed.1000422.g002
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psychosocial barriers to good adherence such as depression and
stigma, which may be better handled through counseling in this
population. External reminders that only inform patients when to
take their pills may be less effective than those electronic devices,
such as cell phone text messages, which can emulate and reinforce
adherence counseling by supporting the relationship between
patient and provider through interactive feedback. In this way, the
positive impact of cell phone text messaging on adherence as
recently demonstrated by Lester et al. may be interpreted as less a
function of the cell phone as a reminder device but rather as a
means to provide regular patient support [47]. The failure of
alarm devices to demonstrate any impact on adherence or
virologic outcomes suggests that contrary to previous assumptions
[48], reminding patients when to take their medication may not be
the primary constraint to adherence in sub-Saharan Africa.
This study enrolled 400 participants and followed them for
18 mo, making it one of the largest and longest, single-site,
randomized trials on adherence interventions and biological
outcomes [21,22,49]. Two distinct and important interventions
were assessed concurrently in a factorial trial, allowing parallel
comparison of interactive counseling and more passive alarm-
reminder interventions as adherence interventions. Multiple
outcomes were regularly measured including manual monthly pill
counts, HIV-1 plasma viral levels, CD4 counts, and mortality.
Participants were antiretroviral naı ¨ve and initiated the same free
HAART regimen: a single fixed-dose combination pill (d4T, 3TC,
nevirapine) taken twice a day. Based in a semi-private mission
hospital in Nairobi and located near Kibera, one of the largest
slums in Africa, the study clinic drew patients from a wide variety
of socioeconomic and educational backgrounds [50]. Adherence
among all study participants were comparable to the generally
high levels found throughout sub-Saharan Africa [4], with 91%
having adherence $80% over 18 mo. These study strengths
support the validity and broad applicability of adherence
counseling among antiretroviral treatment programs in resource-
limited settings.
There are several limitations to the study. The intent-to-treat
analysis was modified to include only those who initiated HAART
since pill count was a necessary method of measuring adherence.
In an analysis comparing those who were lost to follow-up and
those who were retained, the study was biased towards retaining
those who may have been slightly poorer and therefore potentially
more receptive to attentive counseling and free medications. This
may have resulted in associations that are more applicable to a
poorer population. Despite randomization, baseline differences
between intervention arms were noted; these were adjusted for in
multivariable analyses if they were related to the outcome of
interest [36]. Adherence in this study was measured using clinic-
based monthly manual pill counts. Although there is no gold
standard for measuring adherence to medications [51], pill counts
may overestimate adherence since missing pills may not have been
ingested by the participant but instead have been shared,
discarded, or lost [52]. Similarly, use of the alarm device was
measured by self-report and was not able to be verified. It is
possible that continuous use of the alarm device was overestimated
and that the insignificant associations found in this study may have
been due to poor participant participation in this intervention.
The adherence counseling intervention was not associated with
decreased mortality. The lack of an association may have been due
to relatively short follow-up and lack of power due to few mortality
events. Given that virologic failure precedes death due to poor
adherence, the demonstrated impact of adherence counseling on
virologic outcomes in this study suggests that beneficial effects on
mortality might have been apparent if the study was larger and
had longer follow-up [53].
Definitions of viral failure and poor adherence are variable. The
threshold of viral failure in this study was defined using WHO
guidelines (HIV-1 RNA $5,000 copies/ml) [35], and an associ-
ation with adherence counseling was also demonstrated at lower
thresholds (HIV-1 RNA $1,000 copies/ml). However, the
threshold of viral failure may be defined differently [54,55].
Adequate adherence defined as taking $95% of prescribed pills
derives from literature examining regimens containing un-boosted
protease inhibitors (PIs) [11]. The impact of counseling on
adherence ,95% was not significant in this study. An adherence
level of ,80% was defined as poor adherence in this study,
because HAART containing NNRTIs and not PIs were used and
NNRTI-based regimens are most commonly prescribed in
resource-limited settings [5,6]. This definition is supported by
study evidence showing that adherence ,80% was significantly
associated with HIV-1 RNA $5,000 copies/ml.
In summary, we found that intensive counseling on adherence
to antiretroviral medications around the time of HAART initiation
significantly reduced poor adherence and virologic treatment
failure, while using an alarm device had no impact. Investment in
careful individualized counseling at the onset of HAART appears
to have sustained benefit. These findings are highly relevant to
other HIV clinics caring for large numbers of patients in sub-
Saharan Africa. Implementing adherence counseling or interven-
tions that strengthen the relationship between the provider and
patient through communication, education, and trust may
substantially reduce the risk of antiretroviral treatment failure.
Supporting the bond between the clinic and patient in this way
appears to be more effective than using a device that simply
reminds patients when to take their pills. Through interactive
counseling and communication, fewer patients may need to switch
to expensive second-line medications and the spread of resistant
HIV may decrease.
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Background. Adherence to HIV treatment programs in
poor countries has long been cited as an important public
health concern, especially as poor adherence can lead to
drug resistance and inadequate treatment of HIV. However,
two factors have recently cast doubt on the poor adherence
problem: (1) recent studies have shown that adherence is
high in African HIV treatment programs and often better
than in Western HIV clinics. For example, in a meta-analysis
of 27 cohorts from 12 African countries, adequate adherence
was noted in 77% of subjects compared to only 55% among
31 North America cohorts; (2) choice of antiretroviral
regimens may impact on the development of antiretroviral
resistance. In poor countries, most antiretroviral regimens
contain non-nucleoside reverse transcriptase inhibitors
(NNRTIs), such as nevirapine or efavirenz, which remain
in the patient’s circulation for weeks after single-dose
administration. This situation means that such patients may
not experience antiretroviral resistance unless they drop
below 80% adherence—contrary to the more stringent
95% plus adherence levels needed to prevent resistance
in regimens based on unboosted protease inhibitors—
ultimately, off-setting some treatment lapses in resource-
limited settings where NNRTI-based regimens are widely
used.
Why Was This Study Done? Given that adherence may
not be as crucial an issue as previously thought, antiretroviral
treatment programs in sub-Saharan Africa may be spending
scarce resources to promote adherence to the detriment of
some potentially more effective elements of HIV treatment
and management programs. Although many treatment
programs currently include adherence interventions, there
is limited quality evidence that any of these methods
improve long-term adherence to HIV treatment. Therefore,
it is necessary to identify adherence interventions that are
inexpensive and proven to be effective in resource-limited
settings. As adherence counseling is already widely imple-
mented in African HIV treatment programs and inexpensive
alarm devices are thought to also improve compliance, the
researchers compared the impact of adherence counseling
and the use of an alarm device on adherence and biological
outcomes in patients enrolled in HIV programs in rural
Kenya.
What Did the Researchers Do and Find? The researchers
enrolled 400 eligible patients (newly diagnosed with HIV,
never before taken antiretroviral therapy, aged over 18 years)
to four arms: (1) adherence counseling alone; (2) alarm
device alone; (3) both adherence counseling and alarm
device together; and (4) a control group that received
neither adherence counseling nor alarm device. The patients
had blood taken to record baseline CD4 count and HIV-1
RNA and after starting HIV treatment, returned to the study
clinic every month with their pill bottles for the study
pharmacist to count and recorded the number of pills
remaining in the bottle, and to receive another prescription.
Patients were followed up for 18 months and had their CD4
count and HIV-1 RNA measured at 6, 12, and 18 months.
Patients receiving adherence counseling were 29% less likely
to experience poor adherence compared to those who
received no counseling. Furthermore, those receiving
intensive early adherence counseling were 59% less likely
to experience viral failure. However, there was no significant
difference in mortality or significant differences in CD4
counts at 18 months follow-up between those who received
counseling and those who did not. There were no significant
differences in adherence, time to viral failure, mortality,
or CD4 counts in patients who received alarm devices
compared to those who did not.
What Do These Findings Mean? The results of this study
suggest that intensive adherence counseling around the
time of HIV treatment initiation significantly reduces poor
adherence and virologic treatment failure, while using an
alarm device has no effect. Therefore, investment in careful
counseling based on individual needs at the onset of HIV
treatment initiation, appears to have sustained benefit,
possibly through strengthening the relationship between
the health care provider and patient through communica-
tion, education, and trust. Interactive adherence counseling
supports the bond between the clinic and the patient and
may result in fewer patients needing to switch to expensive
second-line medications and, possibly, may help to decrease
the spread of resistant HIV. These findings define an
adherence counseling protocol that is effective and are
highly relevant to other HIV clinics caring for large numbers
of patients in sub-Saharan Africa.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000422.
N UNAIDS provides information about HIV treatment
strategies
N The American Public Health Association has information
about adherence to HIV treatment regimens
N The US Department of Health and Human Services has
information for patients about adherence to HIV treatment
N The World Health Organization provides information about
HIV treatment pharmacovigilance
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